Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : QDEL - Quidel more quick diagnosis -- Ignore unavailable to you. Want to Upgrade?

To: David B. who wrote (1285)	12/18/1997 1:46:00 PM
From: Dennis C	Respond to of 1693

QUIDEL Receives FDA Clearance to Market New, Rapid Pregnancy Tests SAN DIEGO, Dec. 18 /PRNewswire/ -- QUIDEL Corporation (Nasdaq: QDEL - news) today announced it has received U.S. Food and Drug Administration (FDA) clearance to market two new tests designed for use in the clinical laboratory market that detect human chorionic gonadotropin (hCG), the hormone produced during pregnancy. Over 45 million tests for hCG are performed each year in doctors' offices, clinics and emergency rooms generating a market estimated at $50 million dollars annually. hCG is a hormone produced by the placenta shortly after implantation of a fertilized egg. It is present in the serum and urine of pregnant women, making it an excellent market for confirming pregnancy. These new products from Quidel have an enhanced low-end sensitivity that make them excellent choices for clinical use where the determination of an unknown pregnancy can prevent unnecessary procedures from being performed on the mother that could be harmful to the fetus. These new tests are greater than 99% accurate. Test results are available in minutes after the addition of sample with no additional reagents or steps required. The new products are to be sold under the brand names, QuickVue(R) One- Step hCG-Combo, CARDS(R) QS(R) hCG Serum/Urine and CONCISE(R) Performance Plus(TM) hCG-Combo. These tests offer added conveniences over the two current market leaders, such as no pre-treatment of serum samples and room temperature storage. The CARDS QS and CONCISE Performance Plus brands also provide test results in the universally recognized ''+'' sign for a positive results and a ''-'' sign for a negative result. QUIDEL Corporation discovers, develops, manufactures and markets rapid immunodiagnostic products for point-of-care detection of human medical conditions and illnesses. These products provide accurate and cost-effective diagnoses of acute and chronic conditions in the areas of reproductive and women's health, infectious diseases, allergies and autoimmune disorders. QUIDEL's products are sold to professionals in the physician's office and clinical laboratory under the QuickVue, CARDS QS and CONCISE Performance Plus brandnames, as well as to consumers through retail drug stores under the brandnames Conceive(R), QTest(R), RapidVue(R), OvuQuick(R) and OvuKit(R). SOURCE: QUIDEL Corporation

To: David B. who wrote (1285)	12/18/1997 2:00:00 PM
From: Ambrym Man	Read Replies (1) \| Respond to of 1693

Yes, it is always quiet here when the stock is going down. The only bright spot is that the volume is very low. You wrote > Any rumors on who Quidel might be interested in?< I have not heard anything. On Nov 14th in my post 1248 I had raised the spectre of an acquisition. On that day in Yahoo business news, there was an announcement that MEDD was not going to go through with a planned acquisition of the Biotrak product line from Bohringer Mannheim. No reason given. I believe that Andre De Bruin is ex-Bohringer Mannheim. I thought the line looked like a good one for Quidel to pick up. The strange thing is that I have just checked Yahoo for the MEDD news item and it is no longer there. But curiously the first item mentioning the acquisition released in June is still there. Read the June news item for MEDD and see if you think it would suit Quidel. Remember that in the conferance call Quidel mentioned that they were looking to pick up products that were below what the big companies wanted to bother with.